SELL and COVID-19: Considering the significant alterations of NKeff cells subset in COVID-19 patients, a detailed assessment of the immunophenotype of NKeff cells subset was conducted, focusing on markers including CD69, KIR, CD52, CD226, NKG2D, and CD62L using flow cytometry.